INVESTIGATION INTO VERRICA PHARMACEUTICALS CONTINUES by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues Investigation into Officers and Directors of Verrica Pharmaceuticals Inc. – VRCA

Former Louisiana Attorney General Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF is continuing its investigation into Verrica Pharmaceuticals Inc. (NasdaqGM: VRCA).

In December 2020, the Company filed a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (“FDA”) seeking regulatory approval of its lead product, VP-102 or YCANTH, for the treatment of molluscum contagiosum, a skin disease. On September 20, 2021, the Company announced that it had received a Complete Response Letter (“CRL”) due to deficiencies at its contract manufacturer’s facility. In November 2021, the Company resubmitted the NDA, stating that “(the) resubmission relates to the successful resolution of inspection deficiencies” at the manufacturing facility. Subsequently, on May 24, 2022, the Company announced that it had received another Complete Response Letter related to the VP-102 NDA, citing “deficiencies identified during a general re-inspection of Sterling Pharmaceuticals Services, LLC (Sterling), the contract manufacturing organization (CMO) that manufactures Verrica’s bulk solution drug product.”